Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
About this item
Full title
Author / Creator
Castagnetti, F , Gugliotta, G , Breccia, M , Stagno, F , Iurlo, A , Albano, F , Abruzzese, E , Martino, B , Levato, L , Intermesoli, T , Pregno, P , Rossi, G , Gherlinzoni, F , Leoni, P , Cavazzini, F , Venturi, C , Soverini, S , Testoni, N , Alimena, G , Cavo, M , Martinelli, G , Pane, F , Saglio, G , Rosti, G , Baccarani, M , on behalf of the GIMEMA CML Working Party and GIMEMA CML Working Party
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this...
Alternative Titles
Full title
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
Authors, Artists and Contributors
Author / Creator
Gugliotta, G
Breccia, M
Stagno, F
Iurlo, A
Albano, F
Abruzzese, E
Martino, B
Levato, L
Intermesoli, T
Pregno, P
Rossi, G
Gherlinzoni, F
Leoni, P
Cavazzini, F
Venturi, C
Soverini, S
Testoni, N
Alimena, G
Cavo, M
Martinelli, G
Pane, F
Saglio, G
Rosti, G
Baccarani, M
on behalf of the GIMEMA CML Working Party
GIMEMA CML Working Party
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1722168027
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1722168027
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2015.152
